Business Context and Reporting Period
This Form 8-K was filed by Akers Biosciences, Inc. (Ticker: AKER) on December 4, 2019. The Company is an emerging growth company incorporated in New Jersey. The filing reports the formation of a new Advisory Board to assist in a strategic alternatives review, specifically targeting opportunities in the hemp and minor cannabinoid sectors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and strategic direction rather than financial performance data.
Material Changes
- Advisory Board Formation: The Board of Directors established an Advisory Board with expertise in hemp and minor cannabinoids.
- Strategic Pivot: The Company is exploring leveraging its 30-year medical device history, FDA clearances, cGMP operations, and ISO 13485 certification to enter the cannabinoid extraction, testing, and formulation markets.
- Regulatory Assets: The Company highlighted its facility's DEA and New Jersey State certifications for handling Schedules 2, 3, 4, and 5 controlled substances as a competitive advantage.
Outlook, Risks, and Contingencies
Outlook: Management intends to explore pathways to consumer products focused on minor cannabinoids. The Company is continuing its strategic alternatives review.
Risks and Contingencies:
- Nasdaq Listing Status: The filing explicitly states there is no assurance the Company will be granted a hearing or that the panel will determine to continue allowing the listing of its common stock on the Nasdaq Capital Market.
- Forward-Looking Statements: Actual events may differ materially from predictions regarding the strategic review and potential market entry.
Investor Verification Checklist
- Verify the current listing status of AKER on the Nasdaq Capital Market given the explicit warning regarding potential delisting.
- Confirm the composition and specific mandates of the newly formed Advisory Board.
- Review recent financial statements (10-K or 10-Q) to assess liquidity, as this 8-K contains no financial data.
- Monitor for updates on the strategic alternatives review and any potential partnerships or acquisitions in the hemp sector.